Plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer

Dr Alastair Greystoke, senior lecturer, Newcastle University/The Newcastle upon Tyne Hospitals NHS Foundation Trust. Declaration of interest: consultancy fees from AstraZeneca for the development of osimertinib.

Dr Malcolm Lawson, consultant respiratory physician, Mid Essex Hospital Services NHS Trust. No conflicts of interest declared.

Mr Paul Roberts, consultant scientist, Leeds Genetics Laboratory. No conflicts of interest declared.